Reuters reported Tuesday that the London-based firm would not say whether the options that will be looked at by the bank would include a sale.
The company, which had sales of €398m in 2011, is more likely to attract a trade buyer than a private equity firm, according to M&A advisers that spoke to Reuters.
“It is hard to picture the next journey for a private equity owner,” one adviser said.
Bridgepoint bought Diaverum in 2007 and has since expanded the group with over 30 acquisitions.
The company operates about 250 clinics with more than 20,000 patients in 17 countries, up from 155 clinics at the time of Bridgepoint’s buyout, the report said.
Potential buyers could include Germany’s Fresenius and US companies such as Davita Healthcare Partners and Baxter, which JP Morgan helped acquire Sweden’s Gambro from EQT for $4bn in December.
Copyright © 2013 AltAssets